Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Kodiak Sciences (Nasdaq: KOD) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 1:30 p.m. PT.
A live webcast will be available on the company’s Events and Presentations page at http://ir.kodiak.com/ and will remain available for replay for a limited time after the event.
Positive
- None.
Negative
- None.
News Market Reaction – KOD
On the day this news was published, KOD declined 1.66%, reflecting a mild negative market reaction. Argus tracked a peak move of +4.2% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $29M from the company's valuation, bringing the market cap to $1.71B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
KOD gained 8.06% while peers showed mixed, smaller moves: ATYR +3.34%, OLMA +5.95%, ORKA +1.98%, SAGE -0.69%, OPT -2.01%, indicating a stock-specific move rather than a sector-wide shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Equity offering close | Negative | -2.2% | Closed $184M common stock offering at $23.00 per share. |
| Dec 16 | Equity offering pricing | Negative | +4.8% | Priced upsized common stock offering at $23.00 per share. |
| Dec 15 | Proposed equity offering | Negative | -3.3% | Announced proposed underwritten common stock offering under S-3. |
| Nov 13 | Earnings and pipeline | Negative | -6.8% | Reported Q3 loss, low cash, and multiple Phase 3 timelines. |
| Nov 12 | Conference appearances | Neutral | +3.2% | Announced CEO presentations at Jefferies and Evercore conferences. |
Recent equity offerings and earnings with liquidity concerns often coincided with negative price reactions, while neutral conference announcements saw modest gains.
Over the last few months, Kodiak Sciences has focused on financing and advancing late-stage retinal programs. In November 2025, Q3 results highlighted a net loss of $61.5 million and going concern language, which coincided with a -6.81% move. A neutral conferences announcement on Nov 12, 2025 saw shares rise 3.16%. In December 2025, a series of equity offerings around $23.00 per share raised roughly $184 million but brought mostly negative or mixed reactions. Today’s J.P. Morgan conference appearance fits the pattern of investor-relations focused news rather than a fundamental data update.
Market Pulse Summary
This announcement centers on Kodiak’s presentation at the 44th J.P. Morgan Healthcare Conference on January 12, 2026 at 1:30 p.m. Pacific Time. It adds to a pattern of frequent investor-relations events following recent equity offerings and quarterly reports that highlighted substantial losses and late-stage pipeline investment. Investors may watch for updates on Phase 3 timelines, cash usage, and any refinement of strategic priorities, as these topics have driven prior market reactions more than conference logistics alone.
AI-generated analysis. Not financial advice.
A live webcast of the presentation will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases, targeting the
Kodiak®, Kodiak Sciences®, ABC®, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Kodiak's plans, commitments, aspirations and goals related to Kodiak's drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in Kodiak's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in Kodiak's subsequent filings with the SEC. All information in this press release is as of the date presented, and Kodiak undertakes no duty to update such information unless required by law.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-44th-annual-jp-morgan-healthcare-conference-302655850.html
SOURCE Kodiak Sciences Inc.
FAQ
When will Kodiak Sciences (KOD) present at the 44th J.P. Morgan Healthcare Conference?
Where can investors watch the Kodiak Sciences (KOD) presentation from the J.P. Morgan conference?
Will the Kodiak Sciences (KOD) J.P. Morgan presentation be available after the live event?
What topics will Kodiak Sciences (KOD) management likely cover at the January 12, 2026 presentation?
How can I access the Kodiak Sciences (KOD) webcast on January 12 if I am in a different time zone?
Will Kodiak Sciences (KOD) provide a replay or transcript of the J.P. Morgan presentation?
